Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy
NCT02132624Phase 2Completed
- Sponsor
- Uppsala University
- Start
- Apr 2014
- Primary completion
- May 2017
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CD19.CAR-CD28-CD137zeta in B cell lymphoma, B-cell leukemia (BCL), sponsored by Uppsala University. Started Apr 2014; status: completed.
02
Drugs
CD19.CAR-CD28-CD137zeta
03
Conditions
B cell lymphomaB-cell leukemia (BCL)
Beyond the preview
Go deeper on NCT02132624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02132624.